Results 281 to 290 of about 20,692 (311)
Successful dupilumab treatment in a patient with severe dermatitis following allogenic hematopoietic stem cell transplantation. [PDF]
Allergy Asthma Clin ImmunolNam YH, Jin HJ.
europepmc +1 more source
Efficacy and safety of dupilumab in patients with moderate-to-severe atopic dermatitis and comorbid allergic rhinitis. [PDF]
Front Med (Lausanne)Tian T, Li Y, Yuan G, Jiang W.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Dupilumab for the treatment of asthma
Expert Opinion on Investigational Drugs, 2017Dupilumab (REGN668/SAR231893), produced by a collaboration between Regeneron and Sanofi, is a monoclonal antibody currently in phase III for moderate-to-severe asthma. Dupilumab is directed against the α-subunit of the interleukin (IL)-4 receptor and blocks the IL-4 and IL-13 signal transduction. Areas covered: Pathophysiological role of IL-4 and IL-13
Santini, Giuseppe +6 more
openaire +8 more sources
Canadian Journal of Health Technologies, 2023
CADTH recommends that Dupixent should be reimbursed by public drug plans for the treatment of patients aged 6 to younger than 12 years with severe asthma with a type 2/eosinophilic phenotype if certain conditions are met. Dupixent should only be covered for patients with severe asthma aged 6 to younger than 12 years with a type 2 or ...
openaire +1 more source
CADTH recommends that Dupixent should be reimbursed by public drug plans for the treatment of patients aged 6 to younger than 12 years with severe asthma with a type 2/eosinophilic phenotype if certain conditions are met. Dupixent should only be covered for patients with severe asthma aged 6 to younger than 12 years with a type 2 or ...
openaire +1 more source
Dupilumab Facial Redness/Dupilumab Facial Dermatitis: A Guide for Clinicians
American Journal of Clinical Dermatology, 2021Dupilumab facial redness (DFR), or the development of an eczematous rash of the face and neck with dupilumab use, has been observed in recent case reports. It is estimated to impact between 4 and 43.8% of dupilumab users, including children and adults.
Sonal Muzumdar +3 more
openaire +3 more sources
Dupilumab in the Treatment of Asthma
Immunotherapy, 2019Dupilumab is a fully human monoclonal IgG4 antibody that blocks IL-4 and IL-13 signaling. Its efficacy has been assessed across a range of atopic diseases, due to its ability to inhibit T helper cell 2 (Th2) mediated inflammation. It has already been approved in the USA and Europe for the treatment of atopic dermatitis.
Grey, Alice +1 more
openaire +3 more sources